Recruiting Glaucoma Studies in Sacramento
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT)....
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participant...
About Glaucoma Clinical Trials in Sacramento
Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high eye pressure, and is a leading cause of irreversible blindness. Open-angle glaucoma is the most common form. Treatment includes eye drops, laser treatment, and surgery to lower eye pressure.
There are currently 2 glaucoma clinical trials recruiting participants in Sacramento, CALIFORNIA. These studies are seeking a combined 566 participants. Research is being sponsored by Alcon Research, AbbVie. Clinical trial participation is free and participants receive study-related medical care at no cost.
Glaucoma Clinical Trials in Sacramento — FAQ
Are there glaucoma clinical trials in Sacramento?
Yes, there are 2 glaucoma clinical trials currently recruiting in Sacramento, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Sacramento?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you about next steps.
Are clinical trials in Sacramento free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sacramento studies also compensate for your time and travel.
What glaucoma treatments are being tested?
The 2 active trials in Sacramento are testing new therapies including novel drugs, biologics, and treatment approaches for glaucoma.
Data updated March 2, 2026 from ClinicalTrials.gov